Pinteon Therapeutics

Pinteon Therapeutics

Overview

Pinteon Therapeutics is a US biotechnology company developing therapeutics targeting tau protein pathology in Alzheimer's disease and other neurodegenerative disorders. Founded in 2016 and headquartered in San Francisco, California, Pinteon takes a unique approach by targeting specific conformational epitopes of tau that are exposed only in pathological forms of the protein["@pinteon"].

Pinteon Therapeutics

Overview

Pinteon Therapeutics is a US biotechnology company developing therapeutics targeting tau protein pathology in Alzheimer's disease and other neurodegenerative disorders. Founded in 2016 and headquartered in San Francisco, California, Pinteon takes a unique approach by targeting specific conformational epitopes of tau that are exposed only in pathological forms of the protein["@pinteon"].

The company's pioneering conformant antibody technology allows selective targeting of disease-causing tau species while sparing normal tau function, potentially providing therapeutic benefit with improved safety compared to non-selective approaches["@conformant2020"].

Company Overview

| Attribute | Value |
|-----------|-------|
| Ticker | NASDAQ: PNTB (formerly) |
| Founded | 2016 |
| Headquarters | San Francisco, CA |
| CEO | Martin R. Jeffries |
| Status | Private |
| Employees | ~20 |

Funding History

| Round | Year | Amount |
|-------|------|--------|
| Series A | 2016 | $17 million |
| Series B | 2018 | $22 million |
| Series C | 2020 | $30 million |
| IPO | 2020 | $45 million |
| Reverse Merger | 2024 | -- |

Alzheimer's Disease Programs

PNT001

PNT001 is Pinteon's lead clinical candidate, a monoclonal antibody that selectively binds to pathological conformations of tau protein[@pnt2022].

• Mechanism: Monoclonal antibody targeting pathological tau conformations (conformant epitope)
• Target: Pathological tau (disease-specific conformers)
• Phase: Phase 1 (completed)
• Route: Intravenous infusion
• Key Features:
• Selective for pathological tau forms
• Preserves normal tau function
• High affinity for AD and CTE tau

Mechanism of Action

PNT001 targets a specific conformational epitope of tau that is exposed only in pathological aggregates. This selective binding allows:

Clinical Data

PNT001 completed Phase 1 clinical trials in 2022:

• Safety: Well-tolerated at all doses with no serious adverse events
• PK: Dose-proportional exposure with half-life supporting monthly dosing
• Target Engagement: Demonstrated engagement with pathological tau in CSF biomarkers

Pipeline Programs

PNT002 and PNT003

Pinteon's preclinical pipeline includes next-generation conformant antibodies with:

• Enhanced brain penetration
• Improved half-life
• Dual-targeting capabilities

Tau PET Tracer Partnership

Pinteon has collaborated with imaging partners to develop tau PET tracers that can:

• Identify patients with high pathological tau burden
• Monitor treatment response
• Aid in patient selection for clinical trials

Science and Technology

Conformant™ Platform

Pinteon's proprietary Conformant™ platform enables the discovery of antibodies that selectively target pathological protein conformations. This approach addresses a key limitation of earlier tau immunotherapy efforts[@tau2019].

Advantages over traditional anti-tau antibodies:

• Disease-specific targeting
• Reduced mechanism-based toxicity
• Broader therapeutic window
• Potential for earlier intervention

Tau Pathology in Neurodegeneration

Tau protein forms neurofibrillary tangles (NFTs) in Alzheimer's disease, which correlate strongly with cognitive decline. Pathological tau:

• Spreads through neural networks in a prion-like manner
• Impairs synaptic function
• Causes neuronal loss
• Predicts clinical progression better than amyloid

Competitive Landscape

| Company | Drug | Mechanism | Phase |
|--------|------|-----------|-------|
| Biogen | BIIB080 | Tau ASO | Phase 1 |
| Eli Lilly | Semorinemab | Anti-tau mAb | Phase 2 (failed) |
| Roche/Genentech | Semorinemab | Anti-tau mAb | Phase 2 |
| AbbVie | ABBV-8E12 | Anti-tau mAb | Phase 2 |
| Axon Neuroscience | AADvac1 | Tau vaccine | Phase 2 |
| AC Immune | ACI-35 | Tau vaccine | Phase 2 |

• [AD Pipeline Companies](/companies/ad-pipeline-companies)
• [Alzheimer's Disease](/diseases/alzheimers-disease)](/diseases/alzheimers-disease)
• [Tau Protein](/proteins/tau)](/proteins/tau)
• [Biogen](/companies/biogen)
• [AC Immune](/companies/ac-immune)
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Tau immunotherapy](/genes/th)
• [Parkinson's Disease — Tau pathology](/genes/ar)
• [Tau Pathology](/proteins/tau) — Tau-targeted therapies](/genes/ar)
• [Biomarkers - Tau — Tau biomarkers](/genes/ar)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References